|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Aminocaproic acid#Adult Indications and Dosage]] |
| {{Aminocaproic acid}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.
| |
| | |
| Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and [[portacaval shunt]]; hematological disorders such as amegakaryocytic [[thrombocytopenia]] (accompanying [[aplastic anemia]]); acute and life-threatening [[abruptio placentae]]; [[hepatic cirrhosis]]; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.
| |
| Urinary fibrinolysis, usualIy a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS.)<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMICAR (AMINOCAPROIC ACID) SOLUTION AMICAR (AMINOCAPROIC ACID) TABLET [CLOVER PHARMACEUTICALS CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217#nlm34067-9 | publisher = | date = | accessdate = 29 January 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antifibrinolytics]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Amino acids]]
| |
| [[Category:Antifibrinolytics]]
| |
| [[Category:Hematology]]
| |
| | |
| [[ja:Ε-アミノカプロン酸]]
| |
| [[pl:Kwas ε-aminokapronowy]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |